Rare genetic mutation in Amish population linked to ‘bad’ cholesterol levels
Low-density lipoprotein, or LDL, is commonly called “bad” cholesterol since high levels of LDL contribute to a higher risk of coronary heart disease.
A recent study conducted on Amish people, who are unique for genetic studies due to their isolation from the general population, shows a direct association between a novel genetic mutation in the SORT1 gene and human LDL levels. SORT1 is a gene that encodes for the protein sortilin, which previous studies suggest might influence LDL levels. However, functional studies on the gene have so far led to contradictory results.
In collaboration with , this new study led by Kelly Mitok and colleagues at the University of Wisconsin–Madison is the first to establish a direct link between the SORT1 gene and LDL cholesterol.
This discovery can be informative for doctors, especially those who practice precision or personalized medicine. Like clothing that is custom-made to fit a person according to their measurements, precision medicine aims to provide tailored treatments and preventive measures according to an individual’s unique genomic data, environment and lifestyle.
“Every discovery that is made, including ours, is being added continuously to a library of information about the effect each genetic mutation has on humans,” Mitok said. “So when a patient has a SORT1 gene mutation, the doctor can suggest preventive treatment to help reduce their risk of coronary heart disease, because now they know that this SORT1 mutation is linked to LDL levels.”
Working in , Mitok began her work on SORT1 by studying links between SORT1 mutations and Type 2 diabetes. However, progress has been slow with little result. Searching for a new focus, Attie and Mitok asked their colleagues at the Amish Research Clinic if they had found any links between SORT1 mutations and diabetes.
The genetic studies staff informed them of links between SORT1 and LDL-cholesterol.
The researchers collected blood samples from clinical trial participants at the Amish Research Clinic and then conducted whole exome sequencing on the samples. This DNA sequencing technique is used to locate mutations within the exomic, or coding, region of the genome. They also performed clinical lipid panels to measure LDL cholesterol levels. Mitok and her team analyzed these data sets, looking for conclusive evidence for any links between the two.
Their findings, reported in an in the Journal of Lipid Research, showed that one coding mutation in the SORT1gene, called K302E, led to higher levels of LDL cholesterol in the Amish. However, mice studies with this mutation showed contradictory results. An explanation for the contradiction could be due to the difference in metabolism between the two species. This invaluable study will be crucial in informing future research on SORT1gene and its effect on human LDL cholesterol.
Mitok traveled from the University of Wisconsin–Madison to the Old Order Amish community in Lancaster County, Pennsylvania, where she presented her team’s findings to researchers at the Amish Research Clinic and members of the Amish community. She also assisted a member of the clinic in going house to house to recruit Amish individuals to participate in the next clinical study.
“The most rewarding aspect was how this went beyond just getting some data for research,” Mitok said, “It was how the Amish community trusted us like family, inviting us to dinners at their homes and actively participating in the study. This is due to the strong personal connections that the founder and director of the Amish Research Program, Dr. Alan Shuldiner, built with the Amish community from the start.”
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Guiding grocery carts to shape healthy habits
Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.
Quantifying how proteins in microbe and host interact
“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.
Leading the charge for gender equity
Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.
CRISPR gene editing: Moving closer to home
With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.
Finding a missing piece for neurodegenerative disease research
Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.
From the journals: JLR
Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.